Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ATM-3507 is an inhibitor of tropomyosin. In human melanoma cell lines, the IC50s are from 3.83-6.84 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 1,200.00 | |
50 mg | 8-10 weeks | $ 1,560.00 | |
100 mg | 8-10 weeks | $ 2,360.00 |
Description | ATM-3507 is an inhibitor of tropomyosin. In human melanoma cell lines, the IC50s are from 3.83-6.84 μM. |
Targets&IC50 | Tropomyosin (human melanoma cell lines):3.83-6.84 μM |
In vitro | Combining tropomyosin inhibitors with Vincristine induces complete cytotoxicity in CHLA-20 cells, demonstrating varying levels of synergy across four cell lines with differing expressions of Tpm3.1 and other isoforms, as assessed by the Chou–Talalay method. This synergy is not exclusive to vinca alkaloids, with similar enhanced efficacy observed when paclitaxel is paired with either TR100 or ATM-3507[1]. Upon determining the IC50 concentrations for TR100 and ATM-3507 (CHLA-20: 4.99±0.45 µM, CHP-134: 3.83±0.67 µM, CHLA-90: 6.84±2.37 µM, SK-N-BE(2): 5.00±0.42 µM) in neuroblastoma cell lines, combinations of tropomyosin inhibitors with Vincristine were tested. These combinations were effective at doses where each drug alone would kill less than 50% of the cells. |
In vivo | The maximum tolerated dose (MTD) of TR100 and ATM-3507 has been determined to be 60 mg/kg and 150 mg/kg, respectively. Twice-weekly intravenous administration of ATM-3507 has demonstrated synergistic effects, significantly inhibiting tumor growth and extending survival in animals when used in combination compared to each monotherapy alone. Specifically, the median survival for mice treated with the combination therapy increased to over 49 days from 18 days with ATM-3507 monotherapy, without notably affecting body weight. Pharmacokinetic measurements following intravenous administration of ATM-3507 at 30 mg/kg in Balb/c mice (n=3 per time point) revealed a maximal concentration (Cmax) of 5,758 ng/mL, a half-life (t1/2) of 5.01 hours, plasma clearance of 33.8 mL/min/kg, and a volume of distribution at steady state of 7.23 L/kg[1]. The observed mean area under the curve (AUC0-t) in plasma was 14,548 ng/h/mL, indicating the drug's pharmacokinetic profile. |
Molecular Weight | 611.79 |
Formula | C37H46FN5O2 |
CAS No. | 1861449-70-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (408.64 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ATM-3507 1861449-70-8 Others ATM3507 ATM 3507 inhibitor inhibit